Quality of Life Differences in Patients With Typical Atrial Flutter Following Cavotricuspid Isthmus Ablation

Javier García Seara, a, * Francisco Gude, b, c Pilar Cabanas, a José Luis Martínez Sande, a
Xesús Fernández López, a Juliana Elíes, a Josep Brugada Terradellas, d and José Ramón González Juanatey, a, c

INTRODUCTION AND OBJECTIVES: The aim of the study was to assess and measure health-related quality of life (HRQoL) changes in patients with typical atrial flutter following catheter ablation. The outcome was standardized and normalized to the Spanish population adjusted by age and sex.

METHODS: Ninety-five consecutive patients who had undergone cavotricuspid isthmus ablation were included. The SF-36 questionnaire was self-administered before the procedure and at 1-year follow-up. We used the effect size and the standardized response mean as measures of responsiveness to quantify the change in HRQoL and the minimum clinically important difference to assess the smallest difference in score that patients perceived as beneficial.

RESULTS: Of the 95 patients initially included, 88 completed the 1-year follow-up. We observed a large improvement (effect size ≥ 0.8) on the physical functioning, role-physical, general health, and vitality scales and on the physical component summary. We detected a moderate improvement (effect size ≥ 0.5) on the role-emotional, social functioning, and mental health scales and on the mental component summary. On all scales except bodily pain and social activity, the improvement was clinically perceived by patients.

CONCLUSIONS: A clinically significant improvement in HRQoL measures was found in patients with typical atrial flutter who underwent cavotricuspid isthmus catheter ablation.

© 2010 Sociedad Española de Cardiología. Published by Elsevier España, S.L. All rights reserved.
INTRODUCTION

Typical atrial flutter (AFI) is an arrhythmia that originates in the right atrium through a mechanism involving a reentrant circuit around the tricuspid valve that involves the cavotricuspid isthmus (CTI). It is responsible for 75% to 90% of macroreentrant atrial tachycardia.1 CTI ablation is a first-line treatment option for typical recurrent AFI, especially in cases with poor clinical tolerance. It is also indicated in patients in whom AFI develops following pharmacological treatment of atrial fibrillation (AFib) with class I or III drugs.2–4 Studies have shown an improvement in symptoms and quality of life following CTI ablation.5–7 Nevertheless, those studies used the American population as a reference and did not adjust for age and sex, factors that have a significant effect on quality of life.

Furthermore, recent years have seen rapid advances in the assessment of health status, with the incorporation of new quality-of-life measures. Minimum clinically important difference (MCID) and minimum detectable change are relevant concepts for the determination of changes in quality of life following an intervention (responsiveness) and are currently an important area of research. The aim of this study was to evaluate quality-of-life changes in a cohort of unselected, consecutive patients with CTI-dependent AFI referred for radiofrequency catheter ablation. Data were standardized and normalized for the Spanish population, adjusted for age and sex. In addition, we quantified the effect size obtained and expressed the results in terms of MCID to determine whether the improvement in quality of life was sufficient for patients to perceive a significant benefit in terms of symptoms.

METHODS

Study Population

In total, 95 consecutive patients referred to the cardiac electrophysiology laboratory between January 2003 and March 2005 were included in the study. All patients met the following inclusion criteria: a) at least 18 years of age; b) 1 or more episodes of AFI documented by 12-lead electrocardiogram in the last 6 months; c) a history of isolated AFI or predominant AFI with concomitant AFib or AFl following treatment with type I or type III antiarrhythmic drugs for the prevention of AFib; and d) electrophysiologic confirmation of CTI-dependent AFI or CTI permeability if the ablation procedure is performed in sinus rhythm. In that case, the requirement was that there be a common typical electrocardiogram of the clinical episode.

The following exclusion criteria were applied: a) presence of non-CTI-dependent AFI; b) heart surgery or cardiac interventional procedure (coronary angioplasty or pacemaker implantation) in the last 30 days; c) use of an implantable cardioverter defibrillator; d) life expectancy <1 year; and e) inability to complete a quality-of-life questionnaire.

A patient was considered to have a prevalent disease, such as hypertension, diabetes mellitus, hyperlipidemia, pulmonary disease, or arthritis, if the diagnosis had been made by a physician. Obesity was defined as a body mass index >30.

Definitions

Typical flutter: Morphology of the flutter waves in the lower leads characterized by a slow descending slope, followed by a sharp descending slope and a sharp ascending slope, and ending with a low-amplitude positive component that leads into the gradual descending segment of the following flutter wave. The flutter waves are positive in V1 and negative in V6.

Atrial flutter: Wide, positive flutter waves with notches in the lower leads with a negative component that precedes the positive component, and with wide negative waves in V1.

Ablation Procedure

The procedure was undertaken following at least 6 h of fasting. Oral anticoagulation was suspended 2 days before the electrophysiology study and treatment with low-molecular-weight heparin was initiated if the international normalized ratio was <1.5. A standard quadripolar catheter (UscI-Bard Inc.) was used to map the His bundle region, a decapolar catheter (UscI-Bard Inc.) to map the coronary sinus, and a duodecapolar Halo XP catheter (Cordis-Webster Inc.) to map the activation of the anterolateral wall of the right atrium. Radiofrequency energy was applied for a period of 60 s at each point. CTI dependency was confirmed by entrainment when the rhythm at the beginning of the electrophysiology study was AFI or when this was induced in the laboratory. If the patient was in sinus rhythm, bidirectional CTI permeability was confirmed prior to ablation. The aim of the procedure was to achieve bidirectional CTI conduction block.9,10 Bidirectional block was defined through the activation sequence of the electrograms in the right atrium, the bundle of His, and the coronary sinus stimulating at a cycle length of 600 ms from the coronary sinus and from the lower lateral wall of the right atrium. The persistence of bidirectional block was confirmed 20 min after completion of the procedure.

Questionnaire

The SF-36 questionnaire11 was used as an instrument to measure health-related quality of life (HRQol). The questionnaire was completed by patients prior to ablation and at 1-year follow-up. The questionnaire comprises 8 scales or dimensions that are transformed into scores of between 0 and 100, such that the higher the score the better the health status of the patient.11 An additional item, known as the self-reported health transition, measures the change in health status over a period of 1 year, although it is not included in the analysis alongside the 8 dimensions (Table 1). Each of the scales was standardized and normalized for the Spanish population adjusted for age and sex, such that the reference values have a mean (standard deviation [SD]) of 50 (10). Slight changes are defined as differences of more than 4 points, moderate changes as differences of more than 6 points, and large changes as differences of more than 8 points.12–14

Through a combination of the scores on each dimension, the questionnaire allows 2 summary scores to be calculated: the physical component summary (PCS) and the mental component summary (MCS).15 To quantify the response obtained, the effect size (ES) was measured along with the standardized response mean (SRM) for

---

### Abbreviations

AFI: atrial flutter
CTI: cavotricuspid isthmus
ES: effect size
HRQol: health-related quality of life
MCID: minimal clinical important differences
SRM: standardized response mean

---

**Table 1.** Definition of minimal clinical important differences in quality of life scores.

<table>
<thead>
<tr>
<th>Dimension</th>
<th>MCID</th>
</tr>
</thead>
<tbody>
<tr>
<td>Physical component</td>
<td>9</td>
</tr>
<tr>
<td>Mental component</td>
<td>10</td>
</tr>
</tbody>
</table>

---
the minimum important difference (MID). 17,18 This is defined as
d) very small effect, (0.00-0.19).

Another way to quantify the ES is to compare it with
the minimum important difference (MID). 17,18 This is defined as
the smallest measurable difference in health status that corres-
ponds to an important difference in patient symptoms. It is
estimated based on determination of the standard error of
the mean (SEM). The SEM is defined as the standard error in the
observed result that obscures the true result, and its value is
the mean (SEM). The SEM is defined as the standard error in the
estimated based on determination of the standard error of
the baseline group (ES) or the SD of the
difference between the groups (SRM) for each dimension. 16 The ES
does not have units and is quantified as follows: a) large effect,
≥0.8; b) moderate effect, 0.50-0.79; c) small effect, 0.20-0.49; and
d) very small effect, (0.00-0.19).

One way to quantify the MID is to compare it with the
minimum important difference (MID). 17,18 This is defined as
the smallest difference in health status that corres-
ponds to an important difference in patient symptoms. It is
estimated based on determination of the standard error of
SEMs.18 The MID can be used to

The MID is estimated as 1 \times \text{SEM}. 18 The MID can be used to
estimate the MCID. It is defined as the smallest difference in the
score on an item that a patient can perceive as beneficial and that,
in the absence of side effects or excessive cost, would lead to a
change in patient management. The MID and MCID are usually
similar and, in the absence of external criteria, MCID is considered
to be equal to MID.

Floor or ceiling effects are considered if 15% of the patients
obtain the minimum or maximum possible scores, respectively, for
each dimension of the questionnaire.

Follow-up

All patients received programmed clinical follow-up 3, 6, and 12
months after ablation. Any visit to either a cardiologist or the
emergency department was recorded in the patient’s clinical
history. Six months after the procedure, a 7-day Holter monitor
was used to assess asymptomatic events. Oral anticoagulation was
used for 3 weeks after the electrophysiology study and thereafter
according to the guidelines of the European Society of Cardiology. 19

Statistical Analysis

Analysis of the SF-36 scales was performed by t test and
nonparametric Mann-Whitney test according to whether the data
followed a normal distribution or not. The Kolmogorov-Smirnoff
test was used to verify whether the data obeyed a normal
distribution and the Levene test to assess the homogeneity of the
variances. The Wilcoxon test for paired samples was used to
compare the results obtained on the scales at baseline and during
follow-up after ablation. Survival free of arrhythmias (AFib or AFI)
was analyzed using Kaplan-Meier curves.

Ethical Considerations

The study was performed in accordance with the principles of
the Declaration of Helsinki (1975) and was approved by the Clinical
Research Ethics Committee of Galicia. Signed informed consent
was received from all patients.

RESULTS

Clinical Characteristics of the Patients

Of the 104 patients consecutively referred to the cardiac
electrophysiology laboratory for AFI, 95 had typical AFI (CTI
dependent) and were included in the study (Fig. 1). The baseline
characteristics of the patients are shown in Table 2. Hypertension
was reported in almost 50% of patients and 21% did not have
known heart disease. The most frequent concomitant heart disease
was hypertensive heart disease (39%) and 20% had signs of heart
failure. One in every 4 patients was obese and 40% had significant
respiratory disease. Significant arthritis was present in 24% of
cases.

Table 3 shows the characteristics of the arrhythmia. The most
common type of AFI was paroxysmal (56%). Almost 40% of patients
had previously received cardioversion (electrical or pharmacolo-
gical). In 43% of cases, patients had concomitant AFib. Ablation
was performed for a first episode of AFI in 44% of patients. Only 58%were receiving anticoagulation therapy prior to the procedure. In
15% of cases, AFI related to antiarrhythmic drugs was identified,
mostly due to amiodarone. The incidence of tachycardia was 17%.

<table>
<thead>
<tr>
<th>Table 1</th>
<th>Scales on the Short Form-36 Questionnaire</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Scales or Dimensions</strong></td>
<td><strong>No. of Items</strong></td>
</tr>
<tr>
<td>Physical functioning</td>
<td>10</td>
</tr>
<tr>
<td>Role-physical</td>
<td>4</td>
</tr>
<tr>
<td>Bodily pain</td>
<td>2</td>
</tr>
<tr>
<td>General health perceptions</td>
<td>5</td>
</tr>
<tr>
<td>Vitality</td>
<td>4</td>
</tr>
<tr>
<td>Social functioning</td>
<td>2</td>
</tr>
<tr>
<td>Role-emotional</td>
<td>3</td>
</tr>
<tr>
<td>Mental health</td>
<td>5</td>
</tr>
<tr>
<td>Health transition</td>
<td>1</td>
</tr>
</tbody>
</table>

| Analysis of the SF-36 scales was performed by t test and nonparametric Mann-Whitney test according to whether the data followed a normal distribution or not. The Kolmogorov-Smirnoff test was used to verify whether the data obeyed a normal distribution and the Levene test to assess the homogeneity of the variances. The Wilcoxon test for paired samples was used to compare the results obtained on the scales at baseline and during follow-up after ablation. Survival free of arrhythmias (AFib or AFI) was analyzed using Kaplan-Meier curves. |
Follow-up

The initial success rate for the procedure was 100%; bidirectional CTI conduction block was achieved in all patients. No in-hospital deaths occurred. Six patients died during follow-up, of 5 recorded causes: lung cancer, severe aortic stenosis, respiratory failure as a result of severe chronic obstructive pulmonary disease, respiratory infection, and 2 due to sudden death outside of hospital (1 of which was pulmonary thromboembolism). One patient could not complete the quality-of-life questionnaire during follow-up due to neurological sequelae following a cerebrovascular accident. Consequently, 88 patients satisfactorily completed the quality-of-life questionnaires at baseline and during follow-up.

At 12-month follow-up, 13 cases of recurrence of typical AFib (14.6%) were recorded. In 12 cases, reablation of the CTI was carried out and in 1 case electrical cardioversion was used; 24 patients (25%) had episodes of AFib during follow-up, compared with 41 (43%) who had a history of AFib prior to the electrophysiology study. Of the 24 patients who had episodes of AFib during follow-up, 20 (83%) had a prior history of AFib. At 1-year follow-up, AFib-free survival was 85% (Fig. 2A), AFib-free survival was 80% (Fig. 2B), and AFib/AFib-free survival was 67% (Fig. 2C). Three patients had both types of arrhythmia. At 12-month follow-up, 81 patients (91%) were in sinus rhythm, 7 (8%) were in AFib, and 1 (1%) was in AFib.

Sixty-six patients (66%) were receiving anticoagulation therapy at 1-year follow-up and 24 (27%) were receiving antiplatelet therapy. At baseline, 55 patients (58%) were receiving anticoagulation therapy.

At 1-year follow-up, 29 patients (31%) were receiving antiarrhythmic drugs, compared with 54 patients (57%) who received antiarrhythmia treatment prior to ablation.

Quality of Life

Table 4 shows the results on the SF-36 questionnaire at baseline and 1-year follow-up. At baseline, role-physical was the dimension that displayed the greatest reduction compared with the population mean (11.7 points). This was followed by role-emotional (9.7 points), vitality (8.3 points), and mental health (8.1 points). Bodily pain was the least-affected dimension. The mean PCS was higher than the mean MCS. The reduction in PCS and MCS was 5.7 points and 8.8 points, respectively.

At 1-year follow-up, the scores on all of the scales were close to or greater than 50. The mean PCS was higher than the mean MCS. A ceiling effect was observed in the physical function, role-physical, bodily pain, social activity, and role-emotional dimensions.

In a comparison between baseline and follow-up, large differences (>8 points) were observed in physical function, role-physical, vitality, role-emotional, mental health, and MCS, and moderate changes (>6 points) were observed for general health, social activity, and PCS.

The ES and SRM are shown in Table 5. There was a large effect (>0.8) in the magnitude of the change following the procedure for the physical function, role-physical, general health, and vitality dimensions and for PCS. In the role-emotional, social activity, and
mental health dimensions and the MCS, there was a moderate effect (≥0.5), and a small change was observed in the bodily pain dimension.

The MCID was achieved on all dimensions except bodily pain and social activity, such that the change exceeded the minimum required to be clinically perceived by the patient on those dimensions. The PCS and MCS exceeded the threshold established for the MCID.

Patients with AFib significantly improved their quality of life (Table 6). No significant differences were observed between patients who developed AFib during follow-up and those who did not (Table 7). There were no significant differences in the improvement in quality of life between patients with a first episode of AF and those with recurrent AFib.

The Cronbach’s internal consistency coefficient was 0.85 for the scales at both baseline and follow-up, indicating that the values were adequate for between-group comparisons.

DISCUSSION

In this study, we observed a clinically significant improvement in quality of life following CTI ablation in patients with typical AFib. This result was obtained despite the inclusion of patients with concomitant AFib (43%) and a single episode of AF (44%) in the
cohort. Statistically significant improvements were observed on all scales of the SF-36 questionnaire and on the PCS and MCS. When adjusted for the values obtained in the general population, no significant differences were observed in the bodily pain dimension. This is not surprising, since only 7 patients (7.4%) presented with chest pain as the predominant symptom, and substantial changes would therefore not be expected in this dimension.

In the analysis of the magnitude of the change, assessment of ESs standardized and normalized for the Spanish population adjusted for age and sex revealed a large effect on the PCS and a moderate effect on the MCS, indicating a more marked improvement in physical than mental health status. However, we consider the concept of MCID to be a more important expression of quality-of-life changes that facilitates clinical decision-making. The MCID is a parameter of HRQoL that allows determination of whether a perceived benefit in the health status of the patient is sufficient, in the absence of side effects or excessive costs, to justify a change in therapeutic management of the patient.\textsuperscript{16,17} Thus, the magnitude of change in quality of life exceeded the threshold for the MCID on all dimensions except for bodily pain and social activity. Therefore, treatment by ablation of the CTI resulted in a change in health status that was perceived by the patient with a sufficient magnitude for it to be taken into consideration in all patients with typical AFl.

The use of MCID to express HRQoL results is novel in patients with cardiac arrhythmias and has direct clinical implications, since it does not assess whether radiofrequency catheter ablation of the CTI led to a statistically significant benefit in HRQoL but rather whether this benefit, in addition to being statistically significant, was sufficient to justify the consideration of CTI ablation as a therapeutic option for all patients with typical AFl.

Figure 2. Kaplan-Meier curve for survival free from arrhythmias over 12 months of follow-up in patients subjected to ablation of the cavotricuspid isthmus. A, Typical atrial flutter. B, Atrial fibrillation. C, Atrial fibrillation or flutter.
In an earlier study of HRQoL in patients with typical AFib, Calkins et al. demonstrated benefits on 6 of 8 dimensions of the SF-36 questionnaire in a cohort of 150 patients with typical AFib who underwent CTI ablation with 6 months of follow-up. Improvements were not observed in the bodily pain and general health dimensions. In another cohort of 169 patients with typical AFib who also underwent catheter ablation with 6 months of follow-up, Feld et al. reported improvements on 7 of 10 scales on the SF-36 questionnaire. There were no improvements on the bodily pain, general health, and role-emotional dimensions, although the baseline values were already very high (73, 67, and 71 points on the transformed scale, respectively). The PCS and MCS adjusted to the American population was 42 and 50, respectively. In our cohort, the baseline values for bodily pain, general health, and role-emotional were lower (69, 44, and 59 points on the transformed scale, respectively). The PCS and MCS standardized for the Spanish population adjusted for age and sex was 44 and 44, respectively. The cohort reported by Feld et al. was thus less affected by arrhythmia fundamentally in the mental dimensions.

O’Callaghan et al. reported, from a series of 55 patients who underwent CTI ablation with 12 months of follow-up, not only an improvement in HRQoL and a reduction in the frequency and severity of symptoms but also a reduction in the number of hospital admissions and visits to the emergency department due to arrhythmia.

In another study, Lee et al. showed an improvement in general HRQoL using a different questionnaire in a series of 100 patients with 6 months of follow-up. In a multivariate analysis, they found that the presence of AFib prior to ablation was the only factor that was independently associated with a lower improvement in quality of life. In our cohort, patients with AFib significantly improved their quality of life during follow-up. Nevertheless, they had lower scores at the end of follow-up than patients who had not suffered AFib.

Studies of HRQoL following typical AFib that have used the SF-36 questionnaire differ in some ways from our study. First, for obvious reasons, we standardized and normalized the results for the Spanish population rather than the American population. Second, we adjusted for age and sex. Age is the most important factor influencing HRQoL, such that older patients have a worse quality of life. On the SF-36 questionnaire, it has a particular influence on the physical dimensions, which are lower scores with increasing age. Men report better quality of life than women on the SF-36 questionnaire, although the baseline scores are already very high (73, 67, and 71 points on the transformed scale, respectively). The PCS and MCS standardized for the Spanish population adjusted for age and sex was 44 and 44, respectively. The cohort reported by Feld et al. was thus less affected by arrhythmia fundamentally in the mental dimensions.

Finally, we have expressed the results in terms of MCID, which is a parameter that indicates the clinical benefit perceived by the patient following a therapeutic intervention.

Table 4
Quality of Life at Baseline and 1-Year Follow-up, Standardized and Normalized for the Spanish Population, Adjusted for Age and Sex

<table>
<thead>
<tr>
<th></th>
<th>Baseline (n = 95)</th>
<th>Follow-up (n = 88)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Physical functioning</td>
<td>43.9 (11.7)</td>
<td>54.5 (6.6)</td>
</tr>
<tr>
<td>Role-physical</td>
<td>38.3 (11.4)</td>
<td>49.9 (8.8)</td>
</tr>
<tr>
<td>Bodily pain</td>
<td>47.8 (10.8)</td>
<td>51.2 (9.6)</td>
</tr>
<tr>
<td>General health</td>
<td>43.9 (11.7)</td>
<td>54.5 (6.6)</td>
</tr>
<tr>
<td>Vitality</td>
<td>41.7 (10.7)</td>
<td>52.3 (9.7)</td>
</tr>
<tr>
<td>Social activity</td>
<td>43.5 (15.7)</td>
<td>50.6 (11)</td>
</tr>
<tr>
<td>Role-emotional</td>
<td>40.3 (15.7)</td>
<td>49.5 (12.1)</td>
</tr>
<tr>
<td>Mental health</td>
<td>41.9 (11.3)</td>
<td>50.1 (8.9)</td>
</tr>
<tr>
<td>PCS</td>
<td>44.3 (10.1)</td>
<td>52.2 (8.2)</td>
</tr>
<tr>
<td>MCS</td>
<td>41.2 (14.5)</td>
<td>49.4 (11.4)</td>
</tr>
</tbody>
</table>

MCS, mental component summary; PCS, physical component summary. Data are shown as mean (standard deviation).

Table 5
Differences in Quality of Life Standardized and Normalized for the Spanish Population: Effect Size, Standardized Response Mean, and Minimum Clinically Important Difference (n = 88)

<table>
<thead>
<tr>
<th></th>
<th>Mean</th>
<th>ES</th>
<th>SRM</th>
<th>MCID (ES)</th>
<th>MCID (SRM)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Physical functioning</td>
<td>10.4 (10.1)</td>
<td>0.88</td>
<td>1.03</td>
<td>0.62 (0.06)</td>
<td>0.69 (0.07)</td>
</tr>
<tr>
<td>Role-physical</td>
<td>11.8 (12.1)</td>
<td>1.01</td>
<td>0.94</td>
<td>0.75 (0.08)</td>
<td>0.62 (0.07)</td>
</tr>
<tr>
<td>Bodily pain</td>
<td>3.4 (11.2)</td>
<td>0.31</td>
<td>0.3</td>
<td>0.62 (0.07)</td>
<td>0.62 (0.07)</td>
</tr>
<tr>
<td>General health</td>
<td>6.9 (8.6)</td>
<td>0.74</td>
<td>0.8</td>
<td>0.56 (0.06)</td>
<td>0.54 (0.06)</td>
</tr>
<tr>
<td>Vitality</td>
<td>10.7 (10.6)</td>
<td>0.99</td>
<td>1.01</td>
<td>0.59 (0.07)</td>
<td>0.59 (0.07)</td>
</tr>
<tr>
<td>Role-emotional</td>
<td>9.9 (13.1)</td>
<td>0.63</td>
<td>0.76</td>
<td>0.64 (0.07)</td>
<td>0.64 (0.07)</td>
</tr>
<tr>
<td>Social activity</td>
<td>7.6 (11.6)</td>
<td>0.5</td>
<td>0.66</td>
<td>0.58 (0.06)</td>
<td>0.58 (0.06)</td>
</tr>
<tr>
<td>Mental health</td>
<td>8.5 (11.1)</td>
<td>0.74</td>
<td>0.77</td>
<td>0.65 (0.06)</td>
<td>0.65 (0.06)</td>
</tr>
<tr>
<td>PCS</td>
<td>7.8 (9.7)</td>
<td>0.78</td>
<td>0.8</td>
<td>0.62 (0.06)</td>
<td>0.62 (0.06)</td>
</tr>
<tr>
<td>MCS</td>
<td>8.9 (12.7)</td>
<td>0.6</td>
<td>0.7</td>
<td>0.55 (0.06)</td>
<td>0.55 (0.06)</td>
</tr>
</tbody>
</table>

ES, effect size; MCID, minimum clinically important difference; PCS, mental component summary; PCS, physical component summary; SRM, standardized response mean.

Table 7
Differences in Quality of Life Between Follow-up and Baseline According to Whether or Not Atrial Fibrillation Occurred During Follow-up

<table>
<thead>
<tr>
<th></th>
<th>AFib (n = 23)</th>
<th>No AFib (n = 65)</th>
<th>P</th>
</tr>
</thead>
<tbody>
<tr>
<td>Physical functioning</td>
<td>24.1 (23.9)</td>
<td>24.5 (20.1)</td>
<td>.94</td>
</tr>
<tr>
<td>Role-physical</td>
<td>34.3 (39.6)</td>
<td>48.8 (47.3)</td>
<td>.19</td>
</tr>
<tr>
<td>Bodily pain</td>
<td>10.4 (31.6)</td>
<td>9.6 (32.2)</td>
<td>.91</td>
</tr>
<tr>
<td>General health</td>
<td>10.2 (19.4)</td>
<td>17.1 (19.2)</td>
<td>.15</td>
</tr>
<tr>
<td>Vitality</td>
<td>20.4 (26.5)</td>
<td>26.6 (23.1)</td>
<td>.32</td>
</tr>
<tr>
<td>Social activity</td>
<td>16 (19.1)</td>
<td>16.7 (27.1)</td>
<td>.88</td>
</tr>
<tr>
<td>Role-emotional</td>
<td>34.8 (43.2)</td>
<td>30.3 (39.8)</td>
<td>.66</td>
</tr>
<tr>
<td>Mental health</td>
<td>13.2 (21.8)</td>
<td>19.4 (23.6)</td>
<td>.25</td>
</tr>
</tbody>
</table>

AFib, atrial fibrillation. Data are shown as mean (standard deviation).
Limitations

One of the limitations of our study is the presence of a ceiling effect on the role-physical, bodily pain, social activity, and role-emotional dimensions at baseline and on the physical function, role-physical, bodily pain, social activity, and role-emotional dimensions during follow-up. In other words, it is possible that the differences obtained on these dimensions were underestimated and, therefore, that the benefit could be even greater. Furthermore, although not as important from the point of view of improvements in HRQoL, we should mention the presence of a floor effect at baseline on the role-physical and role-emotional dimensions.

Another limitation arises from the prospective nature of the study in a group of older patients with comorbidities. Thus, some patients were lost to follow-up due to death or inability of the patient to respond to a second questionnaire at 12 months. This limitation adds to another derived from the small number of patients recruited. The observational nature of the study, without randomization of the patients to treatment or placebo, precludes the establishment of a causal relationship. These results should therefore be confirmed in appropriately controlled studies.

Finally, we used a general questionnaire for the evaluation of quality of life and did not complement it with a specific questionnaire to assess quality of life in patients with cardiac arrhythmias.

CONCLUSIONS

An improvement in quality of life was observed in a group of patients with typical AFI 1 year after radiofrequency catheter ablation of the CTI.

FUNDING

This study was partially funded by a grant from the Instituto de Salud Carlos III (redINSCOR [RD06/0003/0016 and RD06/0003/0008], redIAPP [RD06/0018/0006]). F. Gude received a grant (BAE09/90052) from Instituto de Salud Carlos III (Ministerio de Ciencia y Tecnología).

CONFLICT OF INTEREST

None declared.